Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment.

Kryczek I, Wei S, Zou L, Altuwaijri S, Szeliga W, Kolls J, Chang A, Zou W.

J Immunol. 2007 Jun 1;178(11):6730-3.

2.

Induction of a distinct CD8 Tnc17 subset by transforming growth factor-beta and interleukin-6.

Liu SJ, Tsai JP, Shen CR, Sher YP, Hsieh CL, Yeh YC, Chou AH, Chang SR, Hsiao KN, Yu FW, Chen HW.

J Leukoc Biol. 2007 Aug;82(2):354-60. Epub 2007 May 15.

PMID:
17505023
3.

Characterizing tumor-promoting T cells in chemically induced cutaneous carcinogenesis.

Roberts SJ, Ng BY, Filler RB, Lewis J, Glusac EJ, Hayday AC, Tigelaar RE, Girardi M.

Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6770-5. Epub 2007 Apr 5.

4.
5.
7.

Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo.

Ge R, Rajeev V, Ray P, Lattime E, Rittling S, Medicherla S, Protter A, Murphy A, Chakravarty J, Dugar S, Schreiner G, Barnard N, Reiss M.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4315-30.

8.

Th17: an effector CD4 T cell lineage with regulatory T cell ties.

Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM.

Immunity. 2006 Jun;24(6):677-88. Review.

9.

Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancer.

Nam JS, Suchar AM, Kang MJ, Stuelten CH, Tang B, Michalowska AM, Fisher LW, Fedarko NS, Jain A, Pinkas J, Lonning S, Wakefield LM.

Cancer Res. 2006 Jun 15;66(12):6327-35.

10.
11.

IL-23 promotes tumour incidence and growth.

Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, Basham B, McClanahan T, Kastelein RA, Oft M.

Nature. 2006 Jul 27;442(7101):461-5. Epub 2006 May 10.

PMID:
16688182
12.

TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells.

Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B.

Immunity. 2006 Feb;24(2):179-89.

13.

Paradoxical roles of the immune system during cancer development.

de Visser KE, Eichten A, Coussens LM.

Nat Rev Cancer. 2006 Jan;6(1):24-37. Review.

PMID:
16397525
14.

Interleukin-17 receptor-like gene is a novel antiapoptotic gene highly expressed in androgen-independent prostate cancer.

You Z, Shi XB, DuRaine G, Haudenschild D, Tepper CG, Lo SH, Gandour-Edwards R, de Vere White RW, Reddi AH.

Cancer Res. 2006 Jan 1;66(1):175-83.

15.

Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009.

Schlingensiepen KH, Schlingensiepen R, Steinbrecher A, Hau P, Bogdahn U, Fischer-Blass B, Jachimczak P.

Cytokine Growth Factor Rev. 2006 Feb-Apr;17(1-2):129-39. Epub 2005 Dec 27. Review.

PMID:
16377233
16.
17.

IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis.

Numasaki M, Watanabe M, Suzuki T, Takahashi H, Nakamura A, McAllister F, Hishinuma T, Goto J, Lotze MT, Kolls JK, Sasaki H.

J Immunol. 2005 Nov 1;175(9):6177-89.

18.

Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma.

Wei S, Kryczek I, Zou L, Daniel B, Cheng P, Mottram P, Curiel T, Lange A, Zou W.

Cancer Res. 2005 Jun 15;65(12):5020-6.

19.
20.

Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.

Zhang Q, Yang X, Pins M, Javonovic B, Kuzel T, Kim SJ, Parijs LV, Greenberg NM, Liu V, Guo Y, Lee C.

Cancer Res. 2005 Mar 1;65(5):1761-9.

Supplemental Content

Support Center